Nature medicine

Timing of immune and chemotherapy treatment in non-small cell lung cancer: a phase 3 trial

Updated

Abstract

The median progression-free survival was 11.3 months for early time-of-day immunochemotherapy compared to 5.7 months for late administration.

  • Patients receiving early time-of-day treatment had a hazard ratio of 0.40 for earlier disease progression compared to those treated later.
  • The median overall survival was 28.0 months for the early group versus 16.8 months for the late group, reflecting a hazard ratio of 0.42 for earlier death.
  • No new safety signals were observed; treatment-related adverse events were consistent with established profiles.
  • Morning circulating CD8 T cells increased in the early treatment group, while they declined in the late group.
  • The ratio of activated to exhausted CD8 T cells was significantly higher in the early treatment group.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Competing interests: The authors declare no competing interests.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free